Foghorn Therapeutics Inc. (FHTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Foghorn Therapeutics Inc. on December 3, 2025. The filing reports a corporate governance event regarding the appointment of a new interim Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Jeff Sacher as Treasurer and interim Chief Financial Officer, effective December 3, 2025. The Company is continuing its search for a permanent CFO.
Management Commentary and Arrangements
- Interim CFO Appointment: Jeff Sacher, age 60, was appointed to the role. He is a 35-year veteran of the biotechnology and investment banking industries.
- Compensation Structure: Mr. Sacher provides services through Danforth Advisors, LLC ("Danforth"). The Company will pay Danforth an agreed-upon hourly rate for these services and reimburse related expenses.
- Background: Mr. Sacher has served as a CFO at Danforth since May 2022. He holds an M.B.A. from Northwestern University's Kellogg School of Management and a B.A. in biology from Cornell University.
- Relationships: There are no family relationships between Mr. Sacher and any other executive officers or directors of the Company.
Investor Verification Checklist
- Verify the hourly rate and expense reimbursement terms agreed upon with Danforth Advisors, LLC.
- Monitor the timeline and progress of the search for a permanent Chief Financial Officer.
- Review Mr. Sacher's prior experience at Danforth and other investment banks for potential conflicts of interest.
- Check for any subsequent filings regarding the permanent CFO appointment or changes to the interim arrangement.